Journal Article Summary
The article investigates the effects of two medications, Semaglutide and Tirzepatide, on alcohol consumption in individuals with obesity. This topic is significant because Alcohol Use Disorder (AUD) is a serious condition that contributes to high mortality rates worldwide and is often inadequately treated. While existing FDA-approved treatments for AUD have limited success, the potential of GLP-1 receptor agonists like Semaglutide and Tirzepatide to reduce alcohol intake could offer new hope for patients struggling with both obesity and alcohol-related issues.
The researchers conducted two studies to gather data. The first study analyzed social media discussions about GLP-1 medications, revealing that a significant portion of posts indicated a reduction in alcohol cravings and consumption. The second study involved 153 participants who were either taking Semaglutide or Tirzepatide or were in a control group not on these medications. Results showed that those on the medications reported significantly lower alcohol intake, fewer binge drinking episodes, and reduced effects of alcohol compared to the control group and their own previous consumption levels.
However, the study has limitations, including reliance on self-reported data, which can introduce bias. The sample was predominantly white and female, suggesting that further research is needed to explore the effects in more diverse populations. Patients should discuss these findings with their healthcare providers, especially if they are considering these medications for weight management or alcohol use issues, to ensure a comprehensive understanding of potential benefits and risks.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Quddos Fatima, Hubshman Zachary, Tegge Allison, Sane Daniel, Marti Erin, Kablinger Anita S., Gatchalian Kirstin M., Kelly Amber L., et al.. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports 2023. DOI: 10.1038/s41598-023-48267-2. PMID: 38017205. PMCID: PMC10684505.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide — 72 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
